Talvey Market Report 2026

Talvey Market Overview

• The Talvey market growth in the historic period has been driven by increasing prevalence of autoimmune disorders, expansion of biologic drug approvals • Market expansion is supported by increasing adoption of personalized immunotherapy, rising investments in biosimilar development • Growth Driver: Rising Autoimmune Disease Prevalence Fuels Market Growth • Market Trend: Regulatory Approvals Drive Competitive Advantage • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Talvey Market?

Talvey is a biosimilar medication used to treat certain autoimmune conditions by targeting and blocking the activity of integrins, proteins involved in inflammation and immune cell movement. It is commonly prescribed for diseases such as multiple sclerosis (MS) and crohn’s disease, where it helps reduce inflammation, prevent relapses, and improve overall patient outcomes. The main types of talvey formulations are 3 mg or 1.5 ml and 40 mg or ml. 3 mg or 1.5 ml formulation refers to a specific dosage of Talvey, where each 1.5 ml contains 3 mg of the active ingredient. It is used for relapsed or refractory multiple myeloma, monotherapy treatment, and is distributed through various channels such as hospital pharmacies, specialty pharmacies, and online pharmacies. It is used by both adults and geriatrics.

What Is The Talvey Market Growth Forecast?

The growth in the forecast period can be attributed to increasing adoption of personalized immunotherapy, rising investments in biosimilar development, expansion of digital patient monitoring tools, growing focus on cost-effective biologic alternatives, increasing long-term treatment adherence initiatives. Major trends in the forecast period include increasing adoption of targeted autoimmune therapies, growing use of biosimilars in chronic disease management, expansion of precision-based treatment protocols, rising focus on long-term disease control, improved patient monitoring and therapy optimization.

Global Talvey Market Segmentation

1) By Formulation: 3mg Or 1.5ml, 40mg Or ml 2) By Clinical Indication: Relapsed Or Refractory Multiple Myeloma, Monotherapy Treatment 3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies 4) By End User: Adult, Geriatric

What Are The Drivers Of The Talvey Market?

The rising prevalence of autoimmune diseases is expected to propel the growth of the talvey market going forward. Autoimmune diseases refer to conditions in which the immune system mistakenly attacks the body's own tissues, mistaking them for harmful invaders. The prevalence of autoimmune diseases is attributed to factors such as genetic predisposition, environmental triggers, lifestyle changes, and increased awareness. Talvey (natalizumab-sztn) is required for autoimmune diseases, as it targets and blocks integrins, preventing immune cells from crossing into the central nervous system and reducing inflammation, which is a key factor in conditions such as multiple sclerosis and Crohn’s disease. For instance, in January 2025, according to the Mayo Clinic, a US-based nonprofit academic medical center, reports that about 15 million people are estimated to have one or more of 105 autoimmune diseases. Therefore, the rising frequency of autoimmune illnesses is driving the growth of the talvey industry. The increasing healthcare expenditure is expected to propel the growth of the talvey market going forward. Healthcare expenditure refers to the total spending on medical services, treatments, hospital care, pharmaceuticals, and other health-related services. Increasing healthcare expenditure is driven by factors such as an aging population, the rise of chronic diseases, and higher demand for healthcare services. Healthcare expenditure is essential for ensuring the accessibility and affordability of Talvey for patients requiring treatment. For instance, in November 2025, according to Organisation for Economic Co-operation and Development, a US-based intergovernmental organization, reported that in 2024, OECD countries are estimated to have allocated around 9.3% of their GDP to health on average. Therefore, the increasing healthcare expenditure is driving the growth of the talvey industry.

Key Players In The Global Talvey Market

Major companies operating in the talvey market are Johnson & Johnson

Global Talvey Market Trends and Insights

Major companies operating in the Talvey market are focusing on obtaining drug approvals to gain a competitive edge in the industry. Drug approval is the process by which regulatory authorities evaluate and authorize a new drug for sale and use, ensuring its safety, efficacy, and quality based on clinical trial data. For instance, in August 2023, the Janssen Pharmaceutical Companies of Johnson & Johnson, a US-based pharmaceutical company, announced the U.S. FDA approval for TALVEY (talquetamab-tgvs), a first-in-class bispecific antibody for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including immunomodulatory drugs, anti-CD38 antibodies, and proteasome inhibitors. TALVEY targets the CD3 receptor on T cells and GPRC5D on multiple myeloma cells, non-malignant plasma cells, and keratinized tissues. Administered as weekly or biweekly subcutaneous injections after a step-up phase, TALVEY offers flexible dosing and was approved under accelerated approval based on response rate and durability.

Regional Insights

North America was the largest region in the talvey market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Talvey Market?

The talvey market consists of sales of biosimilars, monoclonal antibodies, corticosteroids, and immunosuppressants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Talvey Market Report 2026?

The talvey market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the talvey industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.